Hims & Hers Secures $400M Receivables Purchase Facility with JPMorgan
HIMS has more than doubled off its 52-week low of $13.74.
Summary
Hims & Hers secured a new $400 million receivables purchase facility with JPMorgan, enhancing liquidity and working capital without issuing new equity.
Key Events · Financing and Capital Events · HIMS
-
New Receivables Purchase Agreement
Subsidiaries XeCare LLC and Apostrophe Pharmacy LLC entered into a Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A. on July 1, 2026.
-
$400 Million Facility Limit
The agreement provides for a $400 million facility limit, allowing the company to sell eligible receivables for cash, minus an applicable purchase discount.
-
Parent Company Performance Guarantee
Hims & Hers Health, Inc. guarantees the performance of its subsidiaries' obligations under the agreement, but not the collectability of the receivables or the creditworthiness of the sellers.
-
Amendment to Existing Credit Agreement
The company amended its Revolving Credit and Guaranty Agreement to permit the new receivables facility and related obligations, including a new basket for up to $400 million in indebtedness.
Analysis · HIMS · Industrial Applications And Services
Hims & Hers Health, Inc. has established a new $400 million receivables purchase facility with JPMorgan Chase Bank, N.A. This agreement allows its subsidiaries to sell eligible receivables for immediate cash, providing a significant boost to the company's liquidity and working capital. The parent company guarantees the performance of its subsidiaries' obligations under the agreement, but not the collectability of the receivables themselves. This non-dilutive financing mechanism follows a recent $402.5 million convertible note offering and an acquisition, indicating a strategic focus on strengthening cash flow and financial flexibility to support ongoing operations and growth initiatives.
At the time of this filing, HIMS was trading at $37.45 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $13.74 to $70.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.